Revolution Medicines (RVMD) Current Deferred Revenue (2019 - 2023)

Revolution Medicines' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2023.

• On a quarterly basis, Current Deferred Revenue fell 87.46% year-over-year to $1.4 million in Q1 2023; TTM through Mar 2023 was $1.4 million, a 87.46% decrease from a year earlier, with the FY2022 full-year figure at $4.5 million, down 63.92% from the prior year.
• Current Deferred Revenue slipped to $1.4 million in Q1 2023 per RVMD's latest filing, from $4.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $17.1 million in Q4 2019 and bottomed at $1.4 million in Q1 2023.
• The 5-year median for Current Deferred Revenue is $11.8 million (2020), against an average of $11.0 million.
• Across the five-year window, Current Deferred Revenue increased 16.18% in 2022 and tumbled 87.46% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $17.1 million in 2019, then declined by 29.27% to $12.1 million in 2020, then grew by 2.04% to $12.4 million in 2021, then sank by 63.92% to $4.5 million in 2022, then tumbled by 67.84% to $1.4 million in 2023.
• Per Business Quant, the three latest RVMD Current Deferred Revenue figures stand at $1.4 million (Q1 2023), $4.5 million (Q4 2022), and $9.7 million (Q3 2022).